grant

Antagonists of p38 MAPK as therapeutics for acute lymphoblastic leukemia. [ 2008 - 2012 ]

Also known as: New treatments for acute lymphoblastic leukemia

Funded by National Health and Medical Research Council
Managed by The University of Sydney
Managed by University of Sydney
Provided by   National Health and Medical Research Council

Research Grant

[Cite as https://purl.org/au-research/grants/nhmrc/512431]

Researchers: A/Pr Linda Bendall (Principal investigator) ,  Prof Kenneth Bradstock

Brief description New therapies are needed to treat patients with leukemia. Moving leukemic cells into the blood reduces their growth and increases the effects of chemotherapy. Currently we cannot move leukemic cells into the blood without moving normal blood forming cells, making them more sensitive to chemotherapy. We have identified a drug that only affects leukemic cell movement. This study will examine the potential of this drug to treat leukemia.

Funding Amount $AUD 521,961.08

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Help

Related Publications

Related Organisations

Related People

Subjects
321008 | NOD-SCID mouse model | anti-cancer drugs | cancer and related disorders | cell death-apoptosis | haematological malignancy | leukaemia in adults | leukaemia in children | leukemia | pre-B acute lymphoblastic leukemia |
Identifiers
Viewed: [[ro.stat.viewed]]
Saved to MyRDA Save to MyRDA